biapenem

Objective. To conduct a comparative in vitro analysis of the activity of biapenem and meropenem, as well as to evaluate the efficacy of their combinations with colistin against clinical isolates of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa producing carbapenemases of different molecular classes. Materials and Methods. The study included 197 carbapenem-resistant clinical isolates of K. pneumoniae, A. baumannii and P. aeruginosa with a phenotype of multidrug (MDR) and extensively drug (XDR) resistance.

Objective. To assess biapenem PK parameters in critically ill adult patients and define the optimal dosing regimens based on TDM data. Materials and Methods. An open, prospective, uncontrolled, single-center study based on City Clinical Hospital No. 24, Moscow (October 2022 – April 2023), included patients over 18 years of age with a diagnosed severe bacterial infection received 600 mg of biapenem as 3-hour intravenous infusion every 12 hours in the intensive care unit.

Objective. To evaluate in vitro activity of biapenem and other clinically available carbapenems against Russian clinical isolates of Enterobacterales, Pseudomonas aeruginosa и Acinetobacter spp., including isolates with acquired fermentative mechanisms of resistance to β-lactams. Materials and Methods. A total of 3139 Enterobacterales isolates, 793 P. aeruginosa isolates and 634 Acinetobacter spp. isolates from hospitalized patients in 63 hospitals from 35 Russian cities were included in the study during 2018-2019. Minimal inhibitory concentrations (MIC) for biapenem and other antimicrobials were determined in accordance with ISO 20776-1:2006.